A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Part of paid clinical trials in Lafayette, Indiana.

Sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Study ID
NCT05417321
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor
  • NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • HB0036 — DRUG
    Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).

Study Details

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

Key Dates

Start date
Aug 25, 2022
Status verified
Jan 2025
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: HB0036
    HB0036 IV every 3 weeks (q3w)

Primary Outcome Measure

Safety and tolerability [ Time Frame: Up to 12 Months ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Horizon OncologyLafayetteIndiana47905
Albany Constantine, MD/PHD
[email protected]
765-466-5111
Next OncologySan AntonioTexas78229
Anthony Tolcher, MD
[email protected]
210-580-9500
Summit Cancer CentersSpokaneWashington99216
Chaudhry Arvind, MD/PHD
[email protected]
509-462-2273

Find similar trials in Lafayette, IN

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Horizon Oncology· Lafayette, INNext Oncology· San Antonio, TXSummit Cancer Centers· Spokane, WA

Related Studies